VEGFA and macular retinal edema: The aim of this study was to evaluate the effects of intravitreal injection of 0.5 mg/0.05 ml ranibizumab (Lucentis, Genentech, Inc., South San Francisco, CA), a VEGF inhibitor, on visual acuity and anatomic results in treatment of macular edema due to RVO.